AI in Histopathology to Support Prostate & Breast Cancer Diagnosis

NHS England is currently in the planning stage for a public procurement process involving artificial intelligence in histopathology to enhance the diagnosis of prostate and breast cancer. Operating as a central government public authority located in London, they have articulated plans to conduct a preliminary market consultation to refine their commercial strategy in this area. The milestone engagement is set to occur on 17th November 2025, and potential suppliers are invited to express interest and respond to the request for information via the Atamis e-sourcing portal.

This initiative pertains to the services industry with an emphasis on pathology services, medical software packages, imaging equipment, and various other medical devices, and software development services. This procurement presents a significant opportunity for businesses specialising in medical software, imaging equipment, and pathology services to engage with and potentially support NHS England in its innovative undertaking. The project is deemed suitable for SMEs and voluntary, community, and social enterprises, encouraging diverse participation and enabling businesses to expand by contributing to advancements in medical diagnostics.

Companies looking to leverage their expertise in analytical software, medical devices, or related services would be well-positioned to compete in this tender, offering a pathway for growth and increased visibility in the healthcare sector.